Varnimcabtagene Autoleucel - Immuneel Therapeutics
Alternative Names: ARI-0001; IMN-003A; var-celLatest Information Update: 01 Aug 2024
At a glance
- Originator Hospital Clinic de Barcelona; Institut d Investigacions Biomediques
- Developer Hospital Clinic de Barcelona; Immuneel Therapeutics; Institut d Investigacions Biomediques
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Registered Precursor cell lymphoblastic leukaemia-lymphoma
- Clinical Phase Unknown Non-Hodgkin's lymphoma
Most Recent Events
- 30 Jul 2024 Immuneel Therapeutics plans a phase II trial for B-cell malignancies including leukemia and lymphoma
- 09 Dec 2023 Efficacy data from phase I trial in Precursor cell lymphoblastic leukaemia-lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 09 Dec 2023 Updated efficacy and adverse events data from the phase I/II IMAGINE trial in Precursor cell lymphoblastic leukaemia-lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)